Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
General22 hours agoSearch underway for missing boat off South Australia’s Cape Jaffa
-
Noosa News23 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys
-
Noosa News9 hours agoThe Best Things to Do in Brisbane This New Year’s Eve
-
General8 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle